Competitor Analysis: Activators of Immune Checkpoints CD40, GITR, OX40, 4-1BB, CD27 & ICOS
Competitor Analysis: Activators of Immune Checkpoints CD40, GITR, OX40, 4-1BB, CD27 & ICOS
This Competitive Intelligence report about Activators of Immune Checkpoints CD40, GITR, OX40, 4-1BB, CD27 & ICOS provides a competitor evaluation as of November 2016 in the field of antibodies, proteins and vaccines stimulating immune checkpoints from the TNF receptor and the B7-CD28 superfamilies, including
More than 20 immune checkpoint agonistic antibodies are in clinical development as monotherapy or in combination with other checkpoint modulators or targeted cancer therapeutics. At least further six molecules are undergoing IND-enabling studies.
The report includes a compilation of currently active projects in research and development of immune checkpoint activators. In addition, the report lists company-specific R&D pipelines of PD-1 and PD-L1 Immune Checkpoint Inhibitors. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
This Competitive Intelligence report about Activators of Immune Checkpoints CD40, GITR, OX40, 4-1BB, CD27 & ICOS provides a competitor evaluation as of November 2016 in the field of antibodies, proteins and vaccines stimulating immune checkpoints from the TNF receptor and the B7-CD28 superfamilies, including
- CD40 (TNFSFR5)
- GITR (Glucocorticoid-Induced Tumor Necrosis Factor Receptor; TNFSFR18)
- OX40 (CD134; TNFSFR4)
- 4-1BB (CD137; TNFSFR9)
- CD27 (TNFSFR7)
- ICOS (Inducible Co-Stimulator)
More than 20 immune checkpoint agonistic antibodies are in clinical development as monotherapy or in combination with other checkpoint modulators or targeted cancer therapeutics. At least further six molecules are undergoing IND-enabling studies.
The report includes a compilation of currently active projects in research and development of immune checkpoint activators. In addition, the report lists company-specific R&D pipelines of PD-1 and PD-L1 Immune Checkpoint Inhibitors. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
1) Immune Checkpoint Activators
CD40 Agonists
Glucocorticoid-Induced Tumor Necrosis Factor Receptor (GITR) Stimulators
OX40 Agonists
4-1BB (CD137) Agonists
CD27 Agonists
Inducible Co-Stimulator Molecule (ICOS) Agonists
Other Activators
2) Corporate Immune Checkpoint Activators R&D Pipeline
CD40 Agonists
Glucocorticoid-Induced Tumor Necrosis Factor Receptor (GITR) Stimulators
OX40 Agonists
4-1BB (CD137) Agonists
CD27 Agonists
Inducible Co-Stimulator Molecule (ICOS) Agonists
Other Activators
2) Corporate Immune Checkpoint Activators R&D Pipeline
